Latin America Insulin Vials Market Analysis & Forecast: 2026-2033
The Latin America Insulin Vials Market size is anticipated to grow at a CAGR of 8.5% with USD 1,540 Mn in 2026 and is expected to reach USD 2,720 Mn in 2033. The primary drivers are defined by increasing diabetes prevalence, expanding public insulin procurement, hospital-based diabetes management, endocrinology access, and use of human insulin and analogue insulin therapies across Latin America. Some of the other factors include rising Type 1 and Type 2 diabetes diagnosis, stronger retail pharmacy networks, government reimbursement programs, cold-chain distribution improvement, chronic disease screening, and demand from public hospitals, clinics, and tender-based supply channels, where vials remain preferred for multi-dose affordability and institutional dispensing. According to IDF, South and Central America had 35 Mn adults with diabetes in 2024, supporting vial demand.
On the basis of insulin, the long-acting segment is projected to account for the largest Latin America Insulin Vials Market share of 34.5% in 2026. The segment’s growth is owing to the rising need for stable basal glucose control among patients requiring daily insulin therapy, especially in Brazil and Mexico.
Mexico’s National Institute of Public Health reported that diagnosed and undiagnosed diabetes reached 18.3% in 2022, expanding the treated population needing basal insulin support.
In Brazil, the Ministry of Health reported adult diabetes prevalence rose 135% between 2006 and 2024, from 5.5% to 12.9%, strengthening demand for long-duration insulin vials through public and private channels across regional hospitals and clinics.
To learn more about this report, Request Free Sample
On the basis of indication, the type 2 diabetes segment lead with a major 78.2% share in 2026. The segment’s growth is owing to the high treated-patient pool across Latin America, where insulin vials remain essential for dose titration, hospital dispensing, and public-program procurement.
CDC states that Type 2 diabetes accounts for about 90% to 95% of all diagnosed diabetes cases, directly expanding demand for affordable basal and regular insulin vial formats across Latin America.
Mexico’s ENSANUT 2023 further reported 18.4% type 2 diabetes prevalence among adults, with 12.4% diagnosed and 6.0% undiagnosed, showing a large therapy-escalation base.
Brazil is becoming a key innovation center for insulin vial supply in Latin America due to domestic production, technology transfer, and public-sector supply security initiatives. Brazil’s Ministry of Health states that SUS offers comprehensive diabetes care from diagnosis to treatment and provides four types of insulin, including human NPH, regular insulin, rapid-acting analogues, and long-acting analogues. This strengthens insulin vial demand across primary healthcare units, hospitals, and state distribution systems.
In April 2025, Brazil’s Ministry of Health formalized a Productive Development Partnership for insulin glargine which involved Bio-Manguinhos/Fiocruz, Biomm, and Gan & Lee. The project planned production and delivery of nearly 20 million insulin glargine vials in 2025 to serve the SUS patients with both type 1 as well as type 2 diabetes. The development is expected to improve domestic supply resilience and reduce dependence on the imported insulin products.
The Latin America insulin vials market is growing as public health systems expand access to affordable diabetes treatment and improve insulin supply for underserved populations. Rising diabetes prevalence, dependence on injectable insulin in hospitals, and donor-backed supply programs are increasing demand for vial-based insulin across the region.
In April 2026, Direct Relief delivered around 52,000 insulin vials and more than 2.1 million needles and syringes to Ecuador’s Ministry of Public Health. The shipment, supported by Novo Nordisk and embecta, was distributed through Ecuador’s public health system and was expected to provide one month of insulin access for 14% of Ecuadorian people living with diabetes.
The development strengthens the vial-based insulin availability in public hospitals and health facilities, thereby improving treatment continuity for underserved patients and supporting the higher institutional demand for insulin vials across Latin America.
|
Current Event |
Description and its Impact |
|
Brazil SUS Insulin Glargine Transition and Domestic Insulin Production Push
|
|
|
PAHO Strategic Fund and Diabetes Care Strengthening Across the Americas |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Brazil accounts for 36.5% of the market share in 2026. The country’s growth is owing to the large public diabetes treatment base, centralized insulin procurement, and expanding domestic supply security.
Brazil’s Ministry of Health reports that SUS purchases human regular insulin 100 IU/ml and NPH insulin 100 IU/ml in vials and cartridges, then distributes them to state and municipal health warehouses for patients with diabetes. Official Vigitel surveillance also shows diagnosed diabetes among adults in Brazil rose to 9.8% in 2023, sustaining prescription demand.
In February 2026, the Ministry began a gradual SUS transition from NPH to insulin glargine in four states, initially covering more than 50,000 people. The key development is Brazil’s productive-development partnership involving Wockhardt, Funed, and Biomm to manufacture NPH and regular insulin in vials and cartridges, targeting 8 million units by 2026.
Mexico is expected to witness strong growth in Latin America Insulin Vials Market over the forecast period. The growth is owing to the large diabetes treatment base, expanding public diagnosis activity, and continued reliance on injectable insulin in public-care settings.
ENSANUT 2022 reported total diabetes prevalence of about 14.6 million people, creating steady demand for vial-based basal and mealtime insulin through hospitals and public pharmacies. ENSANUT Continua 2022 also indicated increased insulin use for diabetes control across two public health subsystems. This highlights continued scope for public formulary expansion and broader access to insulin vial therapies in Mexico.
A key development came when COFEPRIS included a biocomparable insulin glargine in its therapeutic-extension authorizations for adults and pediatric patients with type 1 and type 2 diabetes, supporting broader affordable long-acting insulin availability across urban and rural Mexico settings.
Some of the major key players in Latin America Insulin Vials Market are Sanofi S.A, Novo Nordisk A/S, and Eli Lilly and Company.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,540 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.5% | 2033 Value Projection: | USD 2,720 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sanofi S.A, Novo Nordisk A/S, and Eli Lilly and Company |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
